Pulse Repetition Time and Contrast Enhancement: Simulation Study of Gd-BOPTA and Conventional Contrast Agent at Different Field Strengths
暂无分享,去创建一个
[1] L Bolinger,et al. High-resolution imaging using Hadamard encoding. , 1999, Magnetic resonance imaging.
[2] K. Uğurbil,et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo , 2007, Magnetic resonance in medicine.
[3] Maximilian F Reiser,et al. Intraindividual Comparison of MR-Renal Perfusion Imaging at 1.5 T and 3.0 T , 2007, Investigative radiology.
[4] P. A. Rinck,et al. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents , 1999, European Radiology.
[5] P. Matthews,et al. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis , 2002, Journal of Neurology.
[6] M. Knopp,et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2004, Radiology.
[7] F. Schick,et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla , 2006, Investigative radiology.
[8] E. Rostrup,et al. Measurement of the arterial concentration of Gd‐DTPA using MRI: A step toward quantitative perfusion imaging , 1996, Magnetic resonance in medicine.
[9] M. Knopp,et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. , 2007, Journal of neurosurgery.
[10] R E Jacobs,et al. A model for MRI contrast enhancement using T1 agents. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] I. Nöbauer-Huhmann,et al. The optimal use of contrast agents at high field MRI , 2006, European Radiology.
[12] G. Bydder,et al. INTRAVENOUS CHELATED GADOLINIUM AS A CONTRAST AGENT IN NMR IMAGING OF CEREBRAL TUMOURS , 1984, The Lancet.
[13] S. H. Koenig. Molecular basis of magnetic relaxation of water protons of tissue. , 1996, Academic radiology.
[14] Sophie Laurent,et al. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.
[15] W. Yuh,et al. A Clinical Comparison of the Safety and Efficacy of MultiHance (Gadobenate Dimeglumine) and Omniscan (Gadodiamide) in Magnetic Resonance Imaging in Patients with Central Nervous System Pathology , 2001, Investigative radiology.
[16] M. Knauth,et al. Low-field interventional MRI in neurosurgery: finding the right dose of contrast medium , 2001, Neuroradiology.
[17] J. Koivukangas,et al. Dynamic MR imaging of brain tumors in low field using undersampled projection reconstruction. , 2004, Magnetic resonance imaging.
[18] D. May,et al. Effect of gadolinium concentration on renal signal intensity: An in vitro study with a saline bag model. , 2000, Radiology.
[19] I. Wilkinson,et al. Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast Agents , 2006, Investigative radiology.
[20] J. Finn,et al. 3.0 Tesla High Spatial Resolution Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of the Pulmonary Circulation: Initial Experience With a 32-Channel Phased Array Coil Using a High Relaxivity Contrast Agent , 2007, Investigative radiology.
[21] T Tolxdorff,et al. Histogram‐based characterization of healthy and ischemic brain tissues using multiparametric MR imaging including apparent diffusion coefficient maps and relaxometry , 2000, Magnetic resonance in medicine.
[22] M. Knopp,et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. , 2006, Radiology.
[23] M. Essig,et al. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. , 2006, Academic radiology.
[24] A. Elster. How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence , 1997, European Radiology.
[25] M. van Buchem,et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children , 2005, Pediatric Radiology.
[26] K. Turetschek,et al. Field strength dependence of MRI contrast enhancement: phantom measurements and application to dynamic breast imaging. , 1996, The British journal of radiology.
[27] M. Reiser,et al. MR imaging of the wrist in rheumatoid arthritis using gadobenate dimeglumine , 2001, Skeletal Radiology.
[28] M. Essig. Gadobenate dimeglumine (MultiHance) in MR imaging of the CNS: studies to assess the benefits of a high relaxivity contrast agent. , 2005, Academic radiology.
[29] C. Hardy,et al. A review of 1H nuclear magnetic resonance relaxation in pathology: are T1 and T2 diagnostic? , 1987, Medical physics.
[30] Wilson Fong. Handbook of MRI Pulse Sequences , 2005 .
[31] J Szumowski,et al. SIMA: Simultaneous Multislice Acquisition of MR Images by Hadamard‐Encoded Excitation , 1988, Journal of computer assisted tomography.
[32] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[33] S. Schoenberg,et al. Brain Tumor Enhancement in MR Imaging at 3 Tesla: Comparison of SNR and CNR Gain Using TSE and GRE Techniques , 2007, Investigative radiology.